Preformulation study for candesartan cilexetil buccal (Effervescent) tablet
Author(s):
K Pansuriya, P Parejiya, D Suthar, P Shelat, A Vekariya and H Patel
Abstract:
Candesartan cilexetil is novel, potent and highly selective non peptide angiotensin II type 1 receptor blocker. It is hydrophobic drug which belongs to BCS Class II drug. For enhancement the bioavability and quick systemic action of candesartan cilexetil a novel formulation of buccal (effervescent) tablet was designed. Preformulation is an important step in the rational formulation of an active pharmaceutical ingredient (API). Micromeritics properties: Bulk density (du), Tapped density (db), Compressibility Index (%C) and sieve analysis was performed in order to determine the best excipients to be used in the formulation development of Candesartan cilexetil (effervescent) tablets. Results show that Candesartan Cilexetil has fair flow and compressibility properties (du 0.8 g/mL, db 0.7 g/mL, %C 12.5 and sieve analysis time 4.5min. HPLC method for estimation of Candesartan cilexetil shows linearity (R2 = 1) and specific with no interference of excipients. Solubility studies reveals that it soluble at pH 6.8 and 7.5 in phosphate buffer. The ability of material to absorb water (Hygroscopicity) was found 0.1% after 24 Hrs at 80% Relative Humidity. Melting point rage from 161-165 °C. There was no any drug excipients interaction was observed when analyzed through FTIR and DSC. There was no change in appearance after 15days at 40°C and 75% Relative humidity. These all results lead to the better development of Candesartan cilexetil buccal (effervescent) tablet.
How to cite this article:
K Pansuriya, P Parejiya, D Suthar, P Shelat, A Vekariya, H Patel. Preformulation study for candesartan cilexetil buccal (Effervescent) tablet. Pharma Innovation 2019;8(12):330-336.